Rznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma

South Korean biopharmaceutical company Rznomics Inc. announced it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) regarding the Orphan Medicinal Product Designation (OMPD) for its investigational therapy RZ-001 (taspitimagene advec) for the treatment of glioma.

RZ-001 is an adenovirus serotype 5-vectored gene therapy utilizing Rznomics' proprietary RNA trans-splicing ribozyme platform. It targets human telomerase reverse transcriptase (hTERT) mRNA, which is overexpressed in 80–90% of human cancers. The therapy replaces the target RNA with a therapeutic RNA encoding the cytotoxic herpes simplex virus thymidine kinase (HSV-TK), thereby selectively inducing apoptosis in cancer cells.

The recommendation stems from interim Phase 1/2a clinical data from patients with recurrent glioblastoma (GBM), a highly aggressive brain cancer subtype. The COMP determined that RZ-001 has sufficient potential to provide a "significant benefit" over existing therapies.

Following formal designation by the European Commission, Rznomics will be eligible for key regulatory and commercial incentives, including up to 10 years of market exclusivity and EMA protocol assistance.